sorafenib has been researched along with ribavirin in 7 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (ribavirin) | Trials (ribavirin) | Recent Studies (post-2010) (ribavirin) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 12,316 | 1,880 | 5,443 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 6 (85.71) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Pár, A; Pár, G | 1 |
Bhoori, S; Germini, A; Lampis, A; Mazzaferro, V; Pellegrinelli, A; Sposito, C; Toffanin, S | 1 |
Amri, A; Arguello, M; Borden, K; Cormack, G; Kraljacic, BC | 1 |
Kudo, M | 1 |
Ahmed, B; Ghaffar, A; Jalal, F; Kamran, SK; Kiran, S; Munir, B; Oranab, S; Shehzadi, S; Zahoor, MK | 1 |
Bakonyi, T; Forgách, P; Gyuranecz, M; Marosi, A; Sulyok, KM | 1 |
2 review(s) available for sorafenib and ribavirin
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Adjuvant therapy after curative treatment for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Clinical Trials as Topic; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Meta-Analysis as Topic; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Pyridines; Recombinant Proteins; Ribavirin; Sorafenib | 2011 |
5 other study(ies) available for sorafenib and ribavirin
Article | Year |
---|---|
[The 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), Milan, Italy, April 23-27, 2008].
Topics: Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Delayed-Action Preparations; Europe; Hepatitis B; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Diseases; Liver Neoplasms; Niacinamide; Oligopeptides; Patient Compliance; Phenylurea Compounds; Polyethylene Glycols; Proline; Pyridines; Recombinant Proteins; Ribavirin; Societies, Medical; Sorafenib | 2008 |
Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; beta Catenin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; DNA Mutational Analysis; Everolimus; Hepatitis C; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Point Mutation; Precision Medicine; Pyridines; Ribavirin; Sirolimus; Sorafenib | 2010 |
Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Binding, Competitive; Clinical Trials, Phase II as Topic; Cytarabine; Drug Synergism; Eukaryotic Initiation Factor-4E; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Ribavirin; RNA Caps; Sorafenib; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2011 |
Sorafenib tosylate, Ribavirn and Sofosbuvir combination therapy for HCV virus infected patients with decompensated liver cancer.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Ribavirin; Sofosbuvir; Sorafenib; Sustained Virologic Response; Treatment Outcome | 2017 |
Evaluation of in vitro inhibitory potential of type-I interferons and different antiviral compounds on rabies virus replication.
Topics: Amides; Animals; Antiviral Agents; Cell Line, Tumor; Drug Combinations; Interferon Type I; Mice; Pyrazines; Rabies virus; Real-Time Polymerase Chain Reaction; Ribavirin; Sorafenib; Virus Replication | 2019 |